Inhibition of SHP2 enhances the effects of selective receptor tyrosine kinase inhibitors in untreated preclinical models of RET-mutated thyroid cancer.

Gavreto (pralsetinib) - Rigel Pharmaceuticals

Retevmo (selpercatinib) - Eli Lilly

SHP099 - Novartis

http://www.ncbi.nlm.nih.gov/pubmed/42649436

Linfei Hu; Mengrang Tian; Ming Gao; Weike Ma; Wenjun Xie; Xiangqian Zheng; Xianhui Ruan; Xing Chen; Ying Sun; Yu Zeng

Aug 27, 2026